Norway Blood Cancer Diagnostics Market Size & Outlook
Norway blood cancer diagnostics market, 2018-2030 (US$M)
Related Markets
Norway blood cancer diagnostics market highlights
- The Norway blood cancer diagnostics market generated a revenue of USD 105.2 million in 2023 and is expected to reach USD 163.9 million by 2030.
- The Norway market is expected to grow at a CAGR of 6.5% from 2024 to 2030.
- In terms of segment, outpatient facilities was the largest revenue generating end use in 2023.
- Research & Manufacturing is the most lucrative end use segment registering the fastest growth during the forecast period.
Blood cancer diagnostics market data book summary
| Market revenue in 2023 | USD 105.2 million |
| Market revenue in 2030 | USD 163.9 million |
| Growth rate | 6.5% (CAGR from 2023 to 2030) |
| Largest segment | Outpatient facilities |
| Fastest growing segment | Research & Manufacturing |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hospitals, Outpatient Facilities, Research & Manufacturing |
| Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Roche Holding AG, Qiagen NV, Becton Dickinson & Co, Siemens Healthineers AG ADR, Thermo Fisher Scientific Inc, Hologic Inc, Koninklijke Philips NV, Illumina Inc |
Other key industry trends
- In terms of revenue, Norway accounted for 1.0% of the global blood cancer diagnostics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany blood cancer diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 644.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Blood Cancer Diagnostics Market Scope
Blood Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway blood cancer diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 65.78% in 2023. Horizon Databook has segmented the Norway blood cancer diagnostics market based on hospitals, outpatient facilities, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
The blood cancer diagnostics market in Norway is expected to have substantial growth, fueled by the country's robust healthcare infrastructure, increasing cancer prevalence, and a strong focus on personalized medicine.
The aging population and improved cancer screening initiatives have led to a rising demand for early & accurate diagnosis of blood cancers like leukemia, lymphoma, and multiple myeloma.
Norway's commitment to precision medicine and genomic testing has accelerated the adoption of advanced diagnostic techniques, such as liquid biopsy tests and genomic profiling assays, which can identify specific biomarkers as well as genetic mutations associated with blood cancers.
Reasons to subscribe to Norway blood cancer diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Norway blood cancer diagnostics market databook
-
Our clientele includes a mix of blood cancer diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway blood cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Norway blood cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Norway blood cancer diagnostics market size, by end use, 2018-2030 (US$M)
Norway Blood Cancer Diagnostics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
